

Functional Parasitic Gastrointestinal Disorders: Unraveling the Overlooked Link.

Mohammed Al-Farsi*

Department of Pathobiology, Sultan Qaboos University, Oman

Functional gastrointestinal disorders (FGIDs) are a broad spectrum of chronic conditions, including irritable bowel syndrome (IBS) and functional dyspepsia, characterized by persistent symptoms without identifiable structural or biochemical abnormalities. While diet, stress, and gut microbiota are often highlighted as key factors, an overlooked yet significant contributor to FGIDs is the potential role of parasitic infections. This commentary delves into how parasitic involvement complicates FGID diagnosis and management and emphasizes the need for a more integrative approach in clinical practice.

The Overlooked Parasite Connection

Parasites are often associated with acute gastrointestinal infections, particularly in resource-limited settings. However, growing evidence suggests that chronic, low-level parasitic infections may trigger or exacerbate FGIDs. For instance, protozoa like *Blastocystis hominis* and *Dientamoeba fragilis* are frequently detected in individuals with IBS-like symptoms. These parasites may not cause overt tissue damage but can disrupt gut function through mechanisms such as:

Immune Activation

Chronic parasitic presence can induce low-grade inflammation and alter gut permeability. This can mimic or contribute to the hypersensitivity seen in FGIDs.

Microbiome Alteration

Parasites can disrupt the delicate balance of gut bacteria, promoting dysbiosis, which is already implicated in FGIDs.

Neuroimmune Modulation

Certain parasites interact with the enteric nervous system, affecting gut motility and visceral sensitivity, key features in disorders like IBS

Diagnostic Challenges

One of the main challenges is distinguishing functional symptoms from parasitic infections. Routine stool tests often miss low-level or intermittent parasitic infections. Advanced diagnostic tools, such as PCR-based stool analysis, are more sensitive but not commonly used in standard practice. Consequently, many patients undergo treatment for FGIDs without considering a parasitic cause, leading to persistent symptoms and frustration.

Clinical Implications: A Call for Integrative Management

Recognizing the potential role of parasites in FGIDs calls for a shift in both diagnostic and therapeutic approaches:

Enhanced Screening Protocols

In patients with refractory FGID symptoms, especially those with a history of travel or unclear symptom origins, advanced parasitic screening should be considered.

Targeted Therapies

If parasites are detected, antiparasitic treatments could significantly improve symptoms. However, indiscriminate use without diagnosis could harm gut microbiota.

Holistic Treatment Plans

Addressing parasites is not enough. Comprehensive management, including dietary modifications, probiotics, and stress reduction, should complement antiparasitic interventions to restore gut balance.

Conclusion

Functional parasitic gastrointestinal disorders represent a critical intersection between infectious disease and chronic gut dysfunction. As our understanding of the gut ecosystem deepens, acknowledging the role of parasitic infections in FGIDs can open new avenues for more effective diagnosis and treatment. This integrative approach not only holds promise for symptom relief but also highlights the intricate complexity of our gut health. Recognizing and addressing these overlooked parasitic contributors could mark a significant step forward in managing the challenging landscape of FGIDs.

References

1. Bornette G, Puijalón S. Response of aquatic plants to abiotic factors: a review. *Aquat Sci.* 2011;73(1):1-4.
2. Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. *N. Engl. J. Med.* 1974;290(20):1110-6.
3. Freeman K, Salt A, Prusa A, et al. Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns, and impairments, in 3 year old children. *BMC pediatrics.* 2005;5(1):1-0.

*Correspondence to: Department of Pathobiology, Sultan Qaboos University, Oman, E-mail: malfarsi.parasite@gmail.com

Received: 27-Sep-2024, Manuscript No. AAPDDT-24-154401; Editor assigned: 01-Oct-2024, PreQC No. AAPDDT-24-154401 (PQ); Reviewed: 15-Oct-2024, QC No. AAPDDT-24-154401; Revised: 22-Oct-2024, Manuscript No. AAPDDT-24-154401 (R); Published: 29-Oct-2024, DOI:10.35841/aapddt-9.4.199

4. Galal L, Hamidovic A, Darde ML, et al. Diversity of *Toxoplasma gondii* strains at the global level and its determinants. *Food and Waterborne Parasitology*. 2019; 15:e00052.
5. Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: to screen or not to screen?. *J Med Screen*. 2002;9(3):135-41.
6. Indexed at, Google Scholar, Cross Ref
7. Pal DK, Nimse SB. Little known uses of common aquatic plant, *Hydrilla verticillata* (Linn. f.) Royle.
8. Raja S, Ramya I. A comprehensive review on *Polygonum glabrum*. *Int J Phytomedic*. 2017;8(4):457-67.
9. Singh A, Mishra A, Chaudhary R, et al. Role of herbal plants in prevention and treatment of parasitic diseases. *J Sci Res*. 2020;64:50-8.
10. Valentini P, Annunziata ML, Angelone DF, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. *Eur J Clin Microbiol Infect Dis*. 2009;28(3):297-300.
11. Vara Prasad MN, de Oliveira Freitas HM. Metal hyperaccumulation in plants: biodiversity prospecting for phytoremediation technology. *Electron J Biotechnol*. 2003;6(3):285-321.